The antibody 2E5 reacts with an extracellular epitope within C-terminal half of TRAIL (APO-2L), a 21 kDa cytotoxic protein, activator of rapid apoptosis in tumor cells. TRAIL is mainly expressed in spleen, lung, prostate and also in many other tissues.
Keine Kreuzreaktivität
Maus
Kreuzreaktivität (Details)
Human
Aufreinigung
Purified by protein-A affinity chromatography.
Reinheit
> 95 % (by SDS-PAGE)
Endotoxin-Niveau
Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.
Immunogen
Recombinant soluble fragment (aa 95-281) of human TRAIL.
TNFSF10
Reaktivität: Human
WB, ELISA, ICC, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Functional application: The antibody 2E5 has high neutralizing activity for human TRAIL in biological assays. Flow cytometry: Recommended dilution: 1-10 μg/mL.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1 mg/mL
Buffer
Phosphate buffered saline (PBS), pH 7.4
Konservierungsmittel
Azide free
Lagerung
4 °C
Informationen zur Lagerung
Store at 2-8°C. Do not freeze.
Plasilova, Zivny, Jelinek, Neuwirtova, Cermak, Necas, Andera, Stopka: "TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors." in: Leukemia, Vol. 16, Issue 1, pp. 67-73, (2002) (PubMed).
Target
TRAIL (TNFSF10)
(Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))
TNF superfamily member 10,Human CD253 / TRAIL (TNF-related apoptosis inducing ligand), also called Apo2, is a type II membrane protein from the TNF family. TRAIL is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apotosis, is achieved through binding to two dealth-signaling receptors, DR4 (CD261 / TRAIL-R1) and DR5 (CD262 / TRAIL-R2).,TRAIL, Apo-2 ligand, Apo-2L, TNFSF10, APO2L, TNLG6A